Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

amgen_flag

Amgen sues Novartis over Enbrel biosimilar

March 3, 2016 Research and Development, Sales and Marketing Amgen, Novartis, Sandoz, biosimilars

Amgen has filed a suit in a US court against Novartis’ generics unit Sandoz, in a bid to protect bestselling …
News
deb_jorn

Valeant company group chairman and executive vice president resigns

March 3, 2016 Medical Communications, Sales and Marketing Valeant, appointed, resignation

In an already troubled week for Valeant Pharmaceuticals, the company has now announced that its group chairman and executive vice …
Appointment
novo_nordisk

Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment

March 2, 2016 Sales and Marketing Novo Nordisk, Xultophy, diabetes

Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification …
News
gilead-sciences

FDA approves Gilead’s Odefsey for treatment of HIV-1 infection

March 2, 2016 Research and Development, Sales and Marketing Gilead Sciences, HIV, Odefsey

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved its TAF-based single tablet regimen Odefsey …
News
janssen_latest_logo_on_sign

Janssen slams NICE decision on Imbruvica

March 2, 2016 Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica

Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …
News
humira_abbott_

Top 10 medicines issued in England by prescription cost in 2014-15

March 2, 2016 Research and Development, Sales and Marketing Cost, Humira, NHS, prescription

AbbVie, Humira (adalimumab), £371m. This drug treats a variety of conditions including psoriatic arthritics, Crohn’s disease and ulcerative colitis. The …
Feature
hilary_clinton_speaks_at_a_rally_in_des_moines_in_january

Clinton steps up attacks on Valeant in latest campaign advert

March 2, 2016 Research and Development, Sales and Marketing Hilary Clinton, Valeant

This is not the first time the pharma industry has drawn the ire of the US presidential hopefuls, but Hilary …
News

LEO Pharma UK/Ireland appoints new dermatology director

March 2, 2016 Medical Communications, Sales and Marketing

LEO Pharma has appointed Michael Hinchy as dermatology director with responsibility for its UK/Ireland affiliate. Michael brings over 16 years …
Appointment
merck_innovation_centre

Merck begins late-stage trials of Humira biosimilar

March 2, 2016 Research and Development, Sales and Marketing AbbVie, Humira, Merck, biosimilars

Merck has announced the beginning of a global phase III study of its Humira (adalimumb) biosimilar, MSB11022, in chronic plaque …
News
ipsen_logo

Exelixis signs $200 million licensing deal for cancer drug

March 1, 2016 Research and Development, Sales and Marketing Cancer, Cometriq, Exelixis, ipsen

Exelixis has signed a licensing agreement with French biotech firm Ipsen for its cancer drug Cometriq (cabozantinib) for an upfront …
News
celgene_1_02

Two Celgene cancer drugs approved in Ireland

March 1, 2016 Research and Development, Sales and Marketing Abraxane, Cancer, Celgene, Revlimid, imnovid

Irish regulators have recommended two cancer treatments from Celgene: Imnovid (pomalidomide), in combination with dexamethasone, for previously-treated relapsed and refractory …
News
drugs_generic

Delivering successful new drugs

March 1, 2016 Manufacturing and Production, Sales and Marketing AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, patents, pharma

Pharma companies are struggling with challenges specific to their industry. Patents for many drugs, that had created massive amounts of …
Feature
astellas

Japan approves Astellas hyperphosphatemia drug

March 1, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Hyperphosphatemia, Japan, Kiklin

Astellas Pharma has received approval from the Ministry of Health, Labour and Welfare in Japan for a supplemental new drug …
News
valeant_logo_on_board

Valeant shares slide on SEC investigation announcement

March 1, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Philidore, Valeant, regulation

Shares at troubled Valeant plummeted some 20% Monday after the company said it was under investigation by the Securities and …
News

AstraZeneca licenses European rights to constipation drug for $70m

March 1, 2016 Manufacturing and Production, Sales and Marketing AstraZeneca, EU, Japan, Luke Miles, ProStrakan Group, constipation drug, moventig

AstraZeneca said on Tuesday it has agreed to licence rights to its constipation drug Moventig to Japan’s ProStrakan Group for …
News
The Gateway to Local Adoption Series

Latest content

IsomAb appoints Philip Brainin as CEO

March 19, 2026

Naobios partners with SGS to manufacture RSV challenge agent

March 19, 2026

Qlaris Bio appoints Fred Guerard as President and CEO

March 18, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

March 18, 2026

AEON Biopharma appoints John Bencich as CFO

March 17, 2026